 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C15H18BrN3O3 |
| Molar mass | 368.231 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MDMB-5Br-INACA is anindazole-3-carboxamide derivative which has been sold as adesigner drug.[2] Surprisingly it has been reported to produce psychoactive activity despite the lack of a "tail" group at the indazole 1-position, but is likely of relatively low potency as a CB1 agonist and has been encountered being misrepresented as other illicit drugs such asMDMA.[3][4] This reported psychoactive activity has been limitedly reported on but could be related to activity beyond the cannabinoid receptors due to vague structural relation to compounds like1Z2MAP1O.
MDMB-5Br-INACA is believed to be used as a precursor in the synthesis of synthetic cannabinoids. It has been sold online as a "chemistry kit" with other compounds required to complete the reaction. This reaction would complete MDMB-5Br-INACA by giving it a "tail" group required for high cannabinoid activity. Other precursors lacking a tail chain have also been marketed such as (ADB-5-Br-INACA),[5] (CH-IATA), (ADB-IACA), and (ADB-5’Br-EZO-CA). This may be due to increasing legality changes worldwide on synthetic cannabinoids.[6][7]
In the United States, MDMB-5Br-INACA is unscheduled at the federal level as of May 22nd, 2023.
North Dakota has placed MDMB-5Br-INACA (along with ADB-5'Br-BINACA,ADB-5'Br-BUTINACA and ADB-5-Br-INACA) into Schedule I on 04/27/2023.[8]
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |
